If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  AUA MEETING: Prostate Cancer Patients Disease Free One Year After Cryocare Treatment SAN DIEGO, CA -- June 1, 1998 -- New data on Endocare's temperature-based targeted ablation technology treatments for prostate cancer show that the procedure is almost 100 percent effective in ridding patients of the cancer for one year following treatment. The data was presented today at the American Urological Association's national meeting in San Diego, CA. The compelling one-year results for the cancer freezing Cryocare technology generated optimistic discussion at this, the nation's largest gathering of urologists. The data points toward temperature-monitored freezing of cancerous tissue as a viable, minimally-invasive method of successfully ridding the body of cancer. Among the announced data was the fact that more than 97 percent of patients who received Endocare's temperature-based treatment for prostate cancer over the past year remain cancer-free (as determined by negative biopsy results). In addition, PSA rates among patients receiving temperature monitored treatment were undetectable and their incontinence rate was less than one percent. Cancer of the prostate is the second most common malignancy in men and the third most common cause of death. In the U.S., the disease afflicts approximately five million men, representing nearly $5 billion US in annual medical treatment costs.
|
